Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection

Journal of Virology

Volumn 85, Issue 21, 2011, Pages 11196-11207

  Liu, Pinghuang ^a   Overman, R Glenn ^a   Yates, Nicole L ^a   Alam, S Munir ^a   Vandergrift, Nathan ^a   Chen, Yue ^a   Graw, Frederik ^c   Freel, Stephanie A ^a   Kappes, John C ^b   Ochsenbauer, Christina ^b   Montefiori, David C ^a   Gao, Feng ^a   Perelson, Alan S ^c   Cohen, Myron S ^d   Haynes, Barton F ^a   Tomaras, Georgia D ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; OPSONIZATION; PRIORITY JOURNAL; VIRION; VIRUS LOAD;

ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY COMPLEX; CHRONIC DISEASE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80055115342     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05601-11     Document Type: Article

References (47)

1. Alam, S. M., et al. 2008. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82:115-125.
2. Bajtay, Z., C. Speth, A. Erdei, and M. P. Dierich. 2004. Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18). J. Immunol. 173:4775-4778.
3. Bouhlal, H., et al. 2002. Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J. Immunol. 169:3301-3306.
4. Bourinbaiar, A. S. 1994. The ratio of defective HIV-1 particles to replication-competent infectious virions. Acta Virol. 38:59-61.
5. Burrer, R., S. Haessig-Einius, A. M. Aubertin, and C. Moog. 2005. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41. Virology 333:102-113.
6. Calarese, D. A., et al. 2005. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl. Acad. Sci. U. S. A. 102:13372-13377.
7. Dianzani, F., et al. 2002. Is human immunodeficiency virus RNA load composed of neutralized immune complexes? J. Infect. Dis. 185:1051-1054.
8. Doria-Rose, N. A., et al. 2005. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J. Virol. 79:11214-11224.
9. Edmonds, T. G., et al. 2010. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408:1-13.
10. Faulkner, D. V., and J. Jurka. 1988. Multiple aligned sequence editor (MASE). Trends Biochem. Sci. 13:321-322.
11. Fiebig, E. W., et al. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17:1871-1879.
12. Forthal, D. N., P. B. Gilbert, G. Landucci, and T. Phan. 2007. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178:6596-6603.
13. Forthal, D. N., et al. 2007. FcgammaRIIa genotype predicts progression of HIV infection. J. Immunol. 179:7916-7923.
14. Freel, S. A., et al. 2010. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J. Virol. 84:4998-5006.
15. Gasper-Smith, N., et al. 2008. Induction of plasma (TRAIL), TNFR-2, Fas ligand and plasma microparticles after HIV-1 transmission: implications for HIV-1 vaccine design. J. Virol. 82:7700-7710.
16. Gorny, M. K., et al. 2002. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol. 76:9035-9045.
17. Haynes, B. F., H. X. Liao, and G. D. Tomaras. 2010. Is developing an HIV-1 vaccine possible? Curr. Opin. HIV AIDS 5:362-367.
18. Jakubik, J. J., M. Saifuddin, D. M. Takefman, and G. T. Spear. 2000. Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes. J. Virol. 74:552-555.
19. Keele, B. F., et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
20. Kimura, M. 1980. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 16:111-120.
21. Kirchherr, J. L., et al. 2007. High throughput functional analysis of HIV-1 env genes without cloning. J. Virol. Methods 143:104-111.
22. Leaman, D. P., H. Kinkead, and M. B. Zwick. 2010. In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J. Virol. 84:3382-3395.
23. Liao, H. X., et al. 2009. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol. Methods 158:171-179.
24. Ma, Z. M., et al. 2009. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J. Virol. 83:3288-3297.
25. McElrath, M. J., and B. F. Haynes. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33:542-554.
26. McMichael, A. J., P. Borrow, G. D. Tomaras, N. Goonetilleke, and B. F. Haynes. 2010. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10:11-23.
27. Moir, S., et al. 2000. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J. Exp. Med. 192:637-646.
28. Moore, P. L., et al. 2006. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80:2515-2528.
29. Morrow, W. J., M. Wharton, R. B. Stricker, and J. A. Levy. 1986. Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus. Clin. Immunol. Immunopathol. 40: 515-524.
30. Nyambi, P. N., et al. 2000. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J. Virol. 74:7096-7107.
31. Perez-Bercoff, D., A. David, H. Sudry, F. Barre-Sinoussi, and G. Pancino. 2003. Fcgamma receptor-mediated suppression of human immunodeficiency virus type 1 replication in primary human macrophages. J. Virol. 77:4081-4094.
32. Pincus, S. H., et al. 2003. In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection. J. Immunol. 170:2236-2241.
33. Platt, E. J., S. L. Kozak, J. P. Durnin, T. J. Hope, and D. Kabat. 2010. Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions. J. Virol. 84:3106-3110.
34. Poignard, P., et al. 2003. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77:353-365.
35. Portera, M., et al. 1990. Free and antibody-complexed antigen and antibody profile in apparently healthy HIV seropositive individuals and in AIDS patients. J. Med. Virol. 30:30-35.
36. Rerks-Ngarm, S., et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
37. Saifuddin, M., et al. 1995. Role of virion-associated glycosylphosphatidyl-inositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 182:501-509.
38. Saitou, N., and M. Nei. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406-425.
39. Shen, X., et al. 2010. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc. Natl. Acad. Sci. U. S. A. 107:5972-5977.
40. Stacey, A. R., et al. 2009. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J. Virol. 83:3719-3733.
41. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
42. Tomaras, G. D., and B. F. Haynes. 2009. HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr. Opin. HIV AIDS 4:373-379.
43. Tomaras, G. D., and B. F. Haynes. 2010. Strategies for eliciting HIV-1 inhibitory antibodies. Curr. Opin. HIV AIDS 5:421-427.
44. Tomaras, G. D., et al. 2008. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82:12449-12463.
45. Vaidya, N. K., R. M. Ribeiro, C. J. Miller, and A. S. Perelson. 2010. Viral dynamics during primary simian immunodeficiency virus infection: effect of time-dependent virus infectivity. J. Virol. 84:4302-4310.
46. Wang, L. X., J. Ni, S. Singh, and H. Li. 2004. Binding of high-mannosetype oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design. Chem. Biol. 11:127-134.
47. Zhu, P., et al. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847-852.